中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.023 seconds)

    ARTIFICIAL NUCLEIC ACID MOLECULES
    1.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES 审中-公开
    人工核酸分子

    公开(公告)号：US20170029847A1

    公开(公告)日：2017-02-02

    申请号：US15195934

    申请日：2016-06-28

    Applicant: CureVac AG

    Inventor： Andreas THESS

    IPC: C12N15/85 ,  C12N15/67

    CPC classification number: C12N15/85 ,  C12N15/67

    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element.

    Abstract translation: 本发明涉及包含至少一个开放阅读框和至少一个3'非翻译区域元件（3'-UTR）元件的人造核酸分子，其包含衍生自核糖体的3'-UTR的核酸序列 蛋白质基因。 本发明还涉及这种人工核酸分子在基因治疗和/或基因疫苗接种中的用途。 此外，本发明涉及包含衍生自核糖体蛋白基因的3'-UTR的核酸序列的3'-UTR元件用于增强，稳定和/或延长来自包含以下的核酸序列的蛋白质表达的用途： 这样的3'-UTR元件。

    RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
    3.
    发明申请
    RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES 有权

    公开(公告)号：US20220296628A1

    公开(公告)日：2022-09-22

    申请号：US17634958

    申请日：2020-08-11

    Applicant: CureVac AG

    Inventor： Andreas THESS ,  Frédéric CHEVESSIER-TÜNNESEN ,  Johannes LUTZ ,  Thomas SCHLAKE

    IPC: A61K31/713 ,  C12N15/117 ,  A61P37/04

    Abstract: The invention relates inter alia to a combination comprising (i) a first component comprising at least one therapeutic RNA and (ii) a second component comprising at least one antagonist of at least one RNA sensing pattern recognition receptor. Further provided are compositions comprising at least one therapeutic RNA and at least one antagonist of at least one RNA sensing pattern recognition receptor. The combination of the two components is able to reduce immunostimulatory properties of the first component as well as promote expression after administration. Additionally, first and second medical uses, and methods of treating or preventing diseases, disorders or conditions are provided.

    NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES
    4.
    发明申请
    NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES 有权

    公开(公告)号：US20220233568A1

    公开(公告)日：2022-07-28

    申请号：US16757289

    申请日：2018-10-17

    Applicant: CureVac AG

    Inventor： Thomas SCHLAKE ,  Andreas THESS ,  Moritz THRAN ,  Frédéric CHEVESSIER-TÜNNESEN ,  Marion PÖNISCH

    IPC: A61K31/7088 ,  C12N15/67 ,  C07K14/47

    Abstract: The present invention provides artificial nucleic acid molecules comprising novel combinations of 5′ and 3′ untranslated region (UTR) elements. The inventive nucleic acid molecules are preferably characterized by increased expression efficacies of coding regions operably linked to said UTR elements. The artificial nucleic acids can be used for treatment or prophylaxis of various diseases. The invention further provides (pharmaceutical) compositions, vaccines and kits comprising said artificial nucleic acid molecules. Further, in vitro methods for preparing artificial nucleic acid molecules according to the invention are provided.

    ARTIFICIAL NUCLEIC ACID MOLECULES
    6.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES 审中-公开

    公开(公告)号：US20190032077A1

    公开(公告)日：2019-01-31

    申请号：US16030018

    申请日：2018-07-09

    Applicant: CureVac AG

    Inventor： Andreas THESS

    IPC: C12N15/85 ,  C12N15/67

    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element.

    ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
    8.
    发明申请
    ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION 有权

    公开(公告)号：US20220002737A1

    公开(公告)日：2022-01-06

    申请号：US17408332

    申请日：2021-08-20

    Applicant: CureVac AG

    Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Stefanie GRUND

    IPC: C12N15/67 ,  A61K39/12 ,  C12N15/85 ,  A61K39/145 ,  A61K39/205 ,  C12N15/68

    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

Patent Agency Ranking